Go to contentGo to menuGo to searchGo to the news list

Micro et Nanomédecines Translationnelles

Main navigation

    Search

    Breadcrumb

    Euronanomed III - RESOLVE (2018-21)

    Euronanomed III - RESOLVE (2018-21)

    • Share this page on social networks
    • E-mail this page

      Send by mail


      Separated by coma
    • Print this page

    Euronanomed III : RESOLVE

    Coordinator : Pr Jean-Pierre BENOIT

    RESOLVE: SuppRESsion of immunopathology by nanOparticle deLiVEry of mRNA to monocytes

     

    The aim of RESOLVE is to pursue the development of innovative nanosystems as novel therapeutic approaches based on the engineering of nanomedicine to limit the immune reactivity against host self-antigens in the course of bone marrow transplantation (graft versus host disease, GvHD) and autoimmune diseases (multiple sclerosis, MS).

    Currently, therapeutics for these pathologies are based on either systemic or local immunosuppression, which eliminate or suppress polyclonal, autoreactive T-cell specificities while compromising the entire systemic immunity with many side effects, sometimes life threatening. But the most promising strategies to come are represented by either restoration or de novo induction of cells able to induce tolerance, such as  the monocytic myeloid-derived suppressor cells (MO-MDSCs). Their immunosuppressive activity, and consequently their tolerogenic ability, can be enhanced by increasing the cellular level of a protein involved in apoptosis regulation, CFLAR. In the course of the present project, new nanosystems will be designed to specifically target in vivo the MO-MDSCs, and efficiently deliver mRNAs to produce CFLAR. The specific expression of the protein, both at the cellular and tissue levels, the in vivo nanosystem biodistribution and the therapeutic efficacy in mouse models of GvHD and MS, will be assessed.

    Consortium

     Jean-Pierre Benoit (Coordinator)

    INSERM U1066/CNRS UMR 6021, University of Angers

    IBS-CHU

    4 Rue Larrey

    49933, Angers, France

     

    Giovanna Lollo

    LAGEP - UMR CNRS 5007 University Claude Bernard Lyon 1

    8 avenue Rockefeller

    69373, Lyon, France

     

    Vincenzo Bronte

    Department of Medicine, University of Verona

    P.le L. A. Scuro, 10

    37134, Verona, Italy

     

    Pål Sætrom

    Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology – NTNU

    Erling Skjalgssons gt. 1

    NO-7491, Trondheim, Norway

     

    Ugur Sahin

    BioNTech RNA Pharmaceuticals

    An der Goldgrube 12

    55131, Mainz, Rhineland-Palatinate, Germany